Table 3 Application, mechanism and peak plasma concentrations for menadione and gemcitabine
From: Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Menadione | Gemcitabine | |
|---|---|---|
Approved application | Used in vitamin K deficiency and severe hypoprothrombinemia | Treatment of locally advanced or metastatic cancer |
Mechanism of action | Synthetic vitamin K3. It is also an inhibitor of Siah2 (E3 ubiquitin ligase) ligase activity | Inhibition of DNA synthesis and inhibition of enzymes related to deoxynucleotide metabolism |
Peak plasma concentration and equivalent in vitro dose | 115–407 ng/mL¶ 668.6 ng–2.3 µM | 3–6 µg/mL 11.2–22.4 µM |
Equivalent in vitro dose | 668.6 ng–2.3 µM | 11.2–22.4 µM |